Kornimate/medical-research-clean huggingface dataset:
cognitive assessment in excessive daytime sleepiness: electrophysiological study.

Conditions: Cognitive Impairment

Summary: cognition was assessed using minimental state examination (mmse), trail making tests a and b (tmt) tests, p300 and quantitative electroencephalography (qeeg) sleepiness was assessed using epworth sleepiness scale (ess), karolinska sleepiness scale (kss) and qeeg also polysomnography (psg) was done for all participated subjects

\*the study is a case control study included 40 subjects, divided into 20 cases suffering from excessive daytime sleepiness and 20 healthy control group. all participants were subjected to: 1. careful history taking and complete neurological examination. 2. initial assessment of cognition and sleepiness by two scales which were done once before sleep: epworth sleepiness scale (ess) and minimental state examination (mmse) 3. scales and neurophysiological studies done before and after sleep:karolinska sleepiness scale (kss), trail making tests a and b (tmt), p300, and qeeg 4. polysomnography (psg) * eeg was recorded for 20 minutes duration before and after sleep recording. in each eeg recording, alpha attenuation test (aat) was done after 10 minutes of recording basal resting eeg, then the absolute power of 5 electrodes (cz, t3, t4, t5, t6,) were studied in the following frequency bands: delta (0.5-3hz), theta (4-7 hz) and also the absolute power of (o1, o2) were studied in delta, theta and alpha (8-12 hz) bands.

Eligibility criteria:
inclusion criteria: * the age ranges from 18 to 60 years. the age of all included subjects was 31-58 yrs old. * the body mass index (bmi) range is 24.97-39.06 kg/m2 in patients and 23.40-43.0 kg/m2 in control group. * patients suffering from excessive daytime sleepiness symptoms according to the international classification of sleep disorders definitions. exclusion criteria: * patients suffering from eds secondary to any sleep disorder other than sleep disordered breathing. * chronic debilitating disease as diabetes mellitus , hypertension or hyper- or hypo-thyroidism. * medications that could affect attention or vigilance as benzodizipines, anti-psychotics or anti-epileptics.
central venous catheter lock solution

Conditions: Bacteremia

Summary: the purpose of this study is to determine whether the application of 47% citrate lock solution decreases the incidence of infection and thrombosis of central venous catheter in hemodialysis population.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of end stage renal disease exclusion criteria: * patients refusing randomization
comparison of insulin detemir with insulin glargine in type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in the united states of america (usa). the purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patients with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * type 2 diabetes for more than 12 months * currently treated with glucose lowering tablets or insulin * hba1c: 7.0-12.0%

Keywords: diabetes, type 2
modified atkins diet in children and adolescents with drug-resistant epilepsy

Conditions: Epilepsy

Summary: the purpose of the study is to evaluate the effect of the modified atkins diet in children and adolescents with drug-resistant epilepsy regarding seizure control, and to create a protocol for the use of the modified atkins diet as a treatment for epilepsy in norway.

the study is a prospective trial on the modified atkins diet for children and adolescents with drug-resistant epilepsy. the modified atkins diet is a less restrictive diet than the classical ketogenic diet, which is usually offered to this group of patients. twenty patients between 2 and 18 years are included in the study, and the study period is 6 months. the study will be conducted at the national centre for child epilepsy in norway.

Eligibility criteria:
inclusion criteria: * age: 2-18 years * at least 3 epileptic seizures per week * tried at least two anti-epileptic drugs without satisfactory seizure control * willing to try diet treatment for 6 months exclusion criteria: * too difficult for the family to adhere to a strict diet * not able to fill in a seizure calendar * local authorities will not approve the treatment * vns stimulator the last 12 months or changes made to vns stimulator during the last three months * other disease where a diet high in fat is contra indicated * diet treatment is not possible because of poor intake of food or fluids * cortisol or other medication that influence energy metabolism or epileptic drug metabolism last month * patient has the last month used alternative medicine which may influence the diet * patient has tried the ketogenic fiet og modified atkins diet the last three years * pregnancy

Keywords: epilepsy diet the modified atkins diet ketogenic diet
efficacy of pergoveris in aged ivf patients

Conditions: Infertility

Summary: to compare the efficacy between lh supplementation (pergoveris) and non-lh supplementation (follitropin alpha) in patients aged ≥ 35 years undergoing ivf treatment. study hypothesis: pergoveris (lh supplementation) is better than follitropin alpha (non-lh supplementation) for ovarian stimulation in aged ivf patients.

a randomized controlled single center study. based on the difference of 19.1% in the clinical pregnancy rate between the two treatment groups, with and without lh supplementation, in a previous study, with 90% power and a 2-sided p-value of 0.05, the number of subjects required was 109 per group (total 218). the recruitment target was 120 subjects per group (total 240) to allow for dropouts. eligible subjects were randomized in blocks of 4 via a computer generated random number list to either the pergoveris arm or the follitropin alpha arm. ovarian stimulation was performed by using gnrh antagonist protocol. follitropin alfa (recombinant fsh) was administered on day 2 or day 3 of the menstrual cycle. the first fsh dose was determined according to each individual patient, based on the process as follows: * afc ≤ 6: 300 iu/day * afc 7-15: 225 iu/day * afc ≥ 16: 150 iu/day gnrh antagonist (cetrotide, merck-serono) was administered on day 5 of fsh administration. * recombinant lh (in the form of pergoveris) was supplemented from day 6 of fsh administration. patients in the pergoveris group would be administered a reduced dose of recombinant fsh (reduced by 150 iu/day) which was replaced with pergoveris (150iu fsh + 75iu lh)/day. * the follitropin alpha group retained recombinant fsh. in both groups, if the number of developing follicles was inappropriate, the dose could be titrated depending on the physician's judgment. monitoring the follicular development was performed by vaginal ultrasound probe, quantifying lh, estradiol and progesterone, starting from day 5 of fsh, based on the current processes of the hospital. opu and embryo transfer: opu was performed 36 hours after hcg administration. embryos were transferred on day 2. luteal phase support: daily vaginal progesterone pregnancy testing and ultrasound: a pregnancy test was done 14 days after embryo transfer. beta hcg \> 5miu/ml was considered positive. fetal ultrasound was performed 3 weeks after a positive pregnancy test to verify clinical pregnancy.

Eligibility criteria:
inclusion criteria: * age ≥ 35 years * body mass index \<28 kg/m2 * had ≤ 3 previous ivf attempts * receiving a gnrh-antagonist protocol * agreement to participate in the study, and to disclose any medical events to the investigator. the subject must be willing and able to comply with the protocol requirements for the duration of the study. * have given written informed consent with the understanding that the subject may withdraw consent at any time exclusion criteria: * participating in another interventional clinical trial * pcos or who group 1 * have uterine abnormalities * have endocrine disorders such as hyperprolactinemia, thyroid disorders

Keywords: ivf lh supplementation ovarian stimulation poor responder
sonographic examination of renal function in individuals with long-term spinal cord injury

Conditions: Spinal Cord Injuries; Renal Insufficiency

Summary: patients with long-term lower urinary tract dysfunction due to spinal cord injury presenting for a routine urodynamic control will be screened for inclusion and exclusion criteria. suitable individuals providing written informed consent will undergo renal doppler sonography and renal scintigraphy in addition to the routine examinations. conclusions regarding renal function based on the clearance rate determined by scintigraphy (gold standard) will be compared with the conclusions based on doppler sonography and cystatin c clearance.


Eligibility criteria:
inclusion criteria: * long-term spinal cord injury (≥10 years) * age ≥30 years * written informed consent exclusion criteria: * dementia or severe intellectual impairment * serious internal illness * previous or current tumor disease * known allergy to the radioactive marker (technetium) * pregnancy or breastfeeding * withdrawal of informed consent
strategies to help adult ed patients quit smoking

Conditions: Tobacco Use

Summary: the purpose of this study is to determine whether a brief, focused intervention in the hospital emergency department is effective in helping adults quit smoking.

in urban communities, the prevalence of tobacco use among adults visiting a hospital emergency department (ed) nears 40%, well in excess of the 25% smoking prevalence rate of the general population. many of these patients lack easy access to primary care, suggesting the ed may be an attractive locus to initiate tobacco cessation efforts. with over 100 million annual visits to u.s. eds, it may be possible to engage millions of smokers in tobacco cessation efforts. the major purpose of this study is to examine whether a multicomponent intervention delivered in the ed by a lay educator to adult smokers interested in quitting is more likely to result in cessation than usual care. a secondary goal is to test whether patients who present to the ed with a tobacco-related illness (as indicated by icd9 code) are more likely to quit than ed smokers with a non-tobacco-related condition. this will allow us to test the validity of the "teachable moment" as an opportune time to engage patients in considering a behavioral change. the proposed study is a randomized trial of a motivational interview, provision of six weeks' worth of nicotine patches, literature, and post-visit follow-up (enhanced care) vs. referral to a cessation clinic (minimal care) for ed patients who smoke. eligibility criteria: age \> 21 years, contemplation or preparation stage of change, not admitted to hospital. all patients will undergo a standardized stage of change assessment, and measurements of nicotine dependence and exhaled carbon monoxide. all will receive a cessation fact sheet and referral card to the smoking cessation clinic; the cards of those in the enhanced care group will have a specific appointment date and time. the enhanced care group will receive a language-appropriate pamphlet discussing smoking cessation. we will record the icd9 codes associated with each visit. major outcome measure: cessation within 3 months of the ed visit, stratified by treatment group. secondary outcome measure: cessation within 3 months of the ed visit, stratified by whether the visit was smoking-related. if smokers receiving enhanced care are more likely to quit, then the ed could be considered a new, effective locus for tobacco control, potentially reaching several million smokers. if patients with a smoking-related diagnosis for the ed visit are more likely to quit than those with non-smoking-related icd9, then this supports the construct of the teachable moment.

Eligibility criteria:
inclusion criteria: * \>= 10 cigarettes smoked daily * being discharged from the ed * contemplation or preparation stage of change * speaks english or spanish exclusion criteria: * being admitted to hospital * too ill to consent

Keywords: tobacco use smoking cessation emergency department
early rehabilitation after hand or wrist ambulatory surgery : how to preserve locomotion at home without rebound pain?

Conditions: Hand Surgery; Wrist Surgery

Summary: the purpose of this retrospective study is to compare the analgesic efficacy of walant " wide awake local anesthesia no tourniquet " with lidocaine and bupivacaine versus axillary brachial plexus block using mepivacaïne, both performed by anesthesiologists, after hand or wrist ambulatory surgery. the main objective is to prove that walant block improve pain relief at home measuring time to first analgesic request. the secondary objectives are to compare maximal pain, consumption of supplementary analgesics, and the duratin of sensory block between groups.

data will be collected on patient records and will be compared between groups of regional anesthesia. data will be : * time to first analgesic request * sensory block * rescue analgesia during the first 24 hours after surgery * maximal pain score during the first 24 hours after surgery * patient satisfaction of managing care

Eligibility criteria:
inclusion criteria: - all adults patients scheduled for hand or wrist ambulatory surgery since 2016 exclusion criteria: - na

Keywords: regional anesthesia walant block
a phase 4, open-label study to assess the feasibility and efficacy on motor and non-motor symptoms of switching from pramipexole or ropinirole to rotigotine transdermal patch in subjects with advanced idiopathic parkinson's disease

Conditions: Advanced Idiopathic Parkinson's Disease

Summary: the purpose of this study is to assess the safety and feasibility of switching subjects with advanced parkinson's disease (pd) from pramipexole or ropinirole to rotigotine and to assess the effects of rotigotine on motor and non-motor symptoms of parkinson's disease in subjects switched from previous treatment with either pramipexole or ropinirole.


Eligibility criteria:
inclusion criteria: * subject has idiopathic parkinson's disease of more than 3 years duration, as defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following: resting tremor, rigidity, impairment of postural reflexes and is without any other known or suspected cause of parkinsonism * subject has motor fluctuations * subject is not satisfactorily controlled following the investigator´s assessment on a total daily dose of pramipexole or ropinirole * subject has sleep disturbance or early morning motor impairment * subject has experienced nocturia for at least 3 nights within 7 days prior to the baseline visit * subject is taking l-dopa in combination with benserazide or carbidopa and has been on a stable dose of l-dopa for at least 28 days prior to the baseline visit exclusion criteria: * subject has had therapy with tolcapone or budipine * subject is receiving therapy with one of the following drugs either concurrently or within 28 days prior to baseline (visit 2): alpha-methyl dopa, metoclopramide, reserpine, neuroleptics, monoamine oxidase a (mao-a) inhibitors, methylphenidate, or amphetamine * subject has a history of symptomatic (not asymptomatic) orthostatic hypotension in the 6 months prior to baseline (visit 2) * subject has a history of significant skin hypersensitivity to adhesive or other transdermal preparations, or recent unsolved contact dermatitis * subject has a history of seizures or stroke within 1 year, or a history of myocardial infarction within the last 6 months prior to enrollment * subject is pregnant or nursing, or is of childbearing potential but (i) not surgically sterile or (ii) not using adequate birth control methods (including at least 1 barrier method) or (iii) not sexually abstinent or (iv) not at least 2 years postmenopausal * subject has a previous diagnosis of narcolepsy, sleep apnea syndrome, restless legs syndrome, or periodic limb movement disorder

Keywords: rotigotine neupro switch dopamine agonists
analysis of the impact of helicobacter pylori on salivary microbiome in adults

Conditions: Helicobacter Pylori Infection

Summary: helicobacter pylori (h. pylori), a bacteria transmitted from human to human through upper digestive tract as well as fecal-oral transmission, had infected more than half of people around the world. however, the quantity of h. pylori in oral cavity and its influence on oral microbiota remains to be unclear. the aim of the present study was to examine the effects of h. pylori infection as well as its eradication on oral microbiota.


Eligibility criteria:
inclusion criteria: * participants with non-ulcer functional dyspepsia or peptic ulcer disease * ability and willingness to participate in the study and to sign and give informed consent * received both endoscopy and 13c urea breath test (13c-ubt) before enrolled exclusion criteria: * less than 18 years old * with previous gastric surgery * major systemic diseases * pregnancy or lactation * allergy to any of the study drugs administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion * the use of antibiotics or ppi within 2 months before the study * the presence of dental carious or any untreated cavitated carious lesions and oral abscesses

Keywords: helicobacter pylori, saliva microbiota
evaluation of sticky bone with or without edta for treatment of gingival recession

Conditions: Gingival Recession

Summary: gingival recession is a common clinical finding in periodontal disease which is frequently associated with esthetic concerns, root hypersensitivity, and root caries. many surgical therapeutic approaches have been developed to predictably obtain root coverage of gingival recession defects. injectable prf (i-prf) is the liquid form of prf. i-prf is a bioactive agent obtained by low-speed centrifugation, and it has the capacity to stimulate tissue regeneration. at high concentrations, prf may stimulate the secretion of several growth factors and trigger fibroblast migration. i-prf is generally used in regenerative treatments, with good outcomes. ethylenediaminetetraaceti acid (edta) is a chelating agent that could enhance the attachment of connective tissue to the root surface by exposing collagen and, as a consequence, enhance root coverage. edta works at neutral ph, and this property has been reported to preserve adjacent tissue vitality. the present study will be carried out to evaluate the effect of sticky bone with or without edta root surface biomodification for treatment of gingival recession.


Eligibility criteria:
inclusion criteria: * miller i/ii isolated maxillary recession defects. * no abrasion, caries, or cervical restorations and presence of identifiable cementoenamel junction (cej). * no occlusal interferences. * full-mouth plaque index (pi) and gingival index (gi) scores of \< 1. * non-smokers. exclusion criteria: * pregnant patients * presence of systemic disease or taking medication that interfere with periodontium

Keywords: i-prf edta
continuous glucose monitor use in school

Conditions: Diabetes Mellitus

Summary: the purpose of this study is to find the impact of continuous blood glucose sensors use in the classroom/school environment. we will be asking the subject,subject's parent and subject's teachers to complete a short survey/questionnaire. the survey will take approximately 10-15 minutes.

the purpose of this study is to find the impact of continuous blood glucose sensors use in the classroom/school environment. recent technological advancements in diabetes management have resulted in increased use of devices during class/school. although many studies have examined the quality of life and the impact on the family and subject of these devices, to our knowledge this is the first study that will examine the impact of the continuous glucose monitor during class/school. to our knowledge, this is first study to involve the teachers. the results of this study is particularly important since the future of diabetes therapy will be to use continuous glucose monitors and insulin pumps to develop a closed loop system of insulin therapy or "artificial pancreas."

Eligibility criteria:
inclusion criteria: diabetes use continuous glucose monitor in school exclusion criteria not using a continuous glucose monitor
use of semen tex101 to improve sperm retrieval rates for men with non-obstructive azoospermia

Conditions: Non-obstructive Azoospermia

Summary: the investigators hypothesize that sperm production varies with time in men with no sperm in semen (non-obstructive azoospermia, noa) and that the semen protein, tex101, is able to monitor these changes. the investigators further hypothesize that tex101 levels may be used to predict the optimum time for microsurgical testicular sperm extraction (mtese) to provide the highest successful rates of sperm retrieval.

this is a non-randomized pilot study. all men with noa, who may or may not consider having mtese, will be approached to enter this study. recruited men will have a semen test performed at the initial visit (time 0) to measure semen tex101 levels using an elisa assay. for men who are not considering a mtese to retrieve sperm, the tex101 semen levels will be measured monthly for three months to determine the variability of semen tex101. for men who are considering a mtese in an attempt to retrieve sperm, the mtese procedure to retrieve sperm will be booked. if the level of tex101 is detectable at time 0, then the men will have semen testing monthly. if the tex101 is persistently detectable then the men will have surgery at the time originally scheduled. if the tex101 drops on any subsequent test to be undetectable, then the semen testing for tex101 will continue monthly for a maximum of 3 additional months. if the tex101 remains undetectable for all tests, the men will have the mtese at the end of the additional 3 months. if the tex101 is detectable on a subsequent test, then the men will undergo an immediate mtese (\< 2 weeks). if the initial tex101 is undetectable, then the men will have monthly semen testing for tex101 for a maximum of 3 additional tests. if the tex101 remains persistently undetectable, then a mtese will be performed as originally booked. if the tex101 is detected on a subsequent test, then an immediate mtese (\< 2 weeks) is performed.

Eligibility criteria:
inclusion criteria: * diagnosed with noa by standard clinical means with a minimum of 2 semen tests confirming that the man is azoospermic * ability to understand the study and consent * ability to deliver semen samples exclusion criteria: * men do not have noa * cannot understand the study and consent * cannot provide semen samples

Keywords: non-obstructive azoospermia sperm retrieval infertility, male semen biomarkers proteomics enzyme-linked immunosorbent assay